VIVUS Cuts QSIVA Price in Bold Move Against New Obesity Injectables

AMSTERDAM – March 25, 2026 – In a direct challenge to the new titans of the weight-loss market, VIVUS B.V. has announced a significant price reduction for its oral obesity medication, QSIVA®, across the Nordic countries and Poland. The move is a calculated strategy to reposition the established drug as a more affordable and accessible alternative to the wildly popular, yet costly, injectable GLP-1 agonists like Wegovy and Mounjaro.

On Wednesday, the biopharmaceutical company confirmed the new pricing strategy, reinforcing the drug's clinical efficacy and safety profile for chronic weight management. QSIVA, a combination of phentermine and topiramate, is indicated for adults with obesity or those who are overweight with related health conditions. The company is betting that in a market grappling with high costs and supply constraints for newer treatments, proven effectiveness combined with affordability will be a powerful combination.

“By combining proven efficacy with improved affordability, we are helping strengthen long-term obesity management strategies across the region,” said John Amos, Chief Executive Officer at VIVUS LLC, in a statement. This move signals a clear intent to compete not just on clinical merit, but on economic grounds, directly addressing one of the biggest barriers to long-term obesity care: cost.

An Affordability Gambit in a High-Cost Market

The price reduction is not a minor adjustment. While the company has not disclosed a single overarching percentage, regional pricing details reveal a substantial change aimed at improving patient access. In Finland, the new price translates to an average daily cost of approximately €3.39. In Denmark, the daily cost is now around 26.63 DKK. VIVUS is framing this in terms of cost-effectiveness, noting the price per kilogram of weight lost is now highly competitive.

For healthcare professionals and patients, this change is significant. The high price of effective obesity medications has long been a source of frustration, often forcing patients to abandon treatments that are working. One Finnish specialist in gynecology and obstetrics, who treats patients with obesity, called the price reduction a welcome development. “Many patients are forced to stop a medication that is working for them simply because the cost is too high,” the specialist noted. “Lowering the price is a step toward more equitable access to effective obesity care—regardless of income.”

This sentiment underscores the central challenge in managing obesity, a chronic disease that requires long-term intervention. By making QSIVA more affordable, VIVUS aims to improve treatment adherence and provide a viable, long-term option for a broader patient population that may have been priced out of the market for effective pharmacological treatments.

The Pill vs. The Pen: A New Front in the Obesity War

VIVUS’s strategy cannot be viewed in a vacuum. It is a direct response to the seismic shift in the obesity treatment landscape caused by the arrival of GLP-1 receptor agonists. Drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro have demonstrated unprecedented efficacy, capturing the attention of patients, physicians, and the media. The market for these drugs is exploding, with projections suggesting it could reach $6.3 billion in Europe by 2032, with GLP-1s accounting for the vast majority of sales.

However, this success comes with challenges. The high price tag of these injectables puts them out of reach for many, and reimbursement by national health systems remains inconsistent. Furthermore, reports indicate a significant patient dropout rate, estimated to be around 50% within the first year, due to side effects, cost, or the burden of weekly injections.

This is where VIVUS sees its opening. QSIVA, an oral pill, offers a different modality and a well-established safety profile from years of clinical use. Data from its pivotal CONQUER trial showed that patients achieved an average weight loss of 7.8% to 10.9% over 56 weeks, results the company emphasizes are clinically meaningful. By positioning QSIVA as a proven, effective, and now more economical option, VIVUS is targeting the segment of the market that is either unwilling or unable to use the newer, more expensive injectables.

Empowering Frontline Healthcare in Chronic Care

The press release from VIVUS specifically highlights the role of pharmacists, positioning them as key partners in the long-term management of obesity. This is a crucial part of the strategy. A more affordable and accessible oral medication empowers a wider range of healthcare professionals, including general practitioners and pharmacists, to take a more active role in obesity care.

For many patients, the journey of managing weight is a marathon, not a sprint. The chronic nature of the disease requires continuous support and accessible treatment options. An affordable pill can be more easily integrated into long-term care plans managed by frontline providers, who can support patients with adherence and lifestyle modifications. This collaborative care model, with pharmacists working alongside prescribers, is essential for managing a public health crisis of this scale. According to the World Health Organization, 43% of adults worldwide were overweight in 2022, and 16% were living with obesity, fueling a rise in related conditions like diabetes and heart disease.

By lowering the financial barrier, VIVUS is not just selling a drug; it is enabling a more sustainable and scalable approach to chronic disease management within existing healthcare structures.

Navigating Reimbursement and Patient Access

The ultimate success of this strategy will hinge on how it influences reimbursement and patient access across different national health systems. The landscape for obesity drug coverage is a complex patchwork. In Poland, for example, the market for GLP-1 drugs has surged despite limited reimbursement for obesity, with a large portion of sales being paid for out-of-pocket by patients.

This demonstrates a significant demand and willingness to pay for effective treatments, but it also highlights a gap that a lower-cost alternative like QSIVA could fill. A more competitive price point makes QSIVA a more attractive candidate for inclusion in national formularies and could persuade private insurers to offer more favorable coverage. It also provides a more manageable out-of-pocket expense for patients in markets where reimbursement is not available.

VIVUS has already signaled its intent to expand QSIVA's reach into 11 additional European countries and the UAE. This price reduction in key initial markets serves as a powerful test case and a statement of intent. The company is making a clear bet that in the global fight against obesity, accessibility and affordability will ultimately be as important as innovation itself. This decision could reshape patient choices and force competitors to reconsider their own pricing strategies in the long run.